TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07213973: Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Sponsor: Incyte Corporation · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 40 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$1,986,600

Rescue Site Savings

+$1,315,800

Unlock Full NCT07213973 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07213973 Rescue Dossier →